Examination of the importance of RUNX category in EGFR wild-type non-small cell lung cancer

被引：0

作者：

Kobayakawa, Atsushi ^{[1
]}

Takeda, Kanako ^{[1
]}

Masuda, Tatuya ^{[1
]}

Yanagida, Yohei ^{[1
]}

Obi, Natsuno ^{[1
]}

Sakuramoto, Naoya ^{[1
]}

Hada, Asuka ^{[1
]}

Horiuchi, Ayaka ^{[1
]}

Takeda, Mizuho ^{[1
]}

Sasaki, Asami ^{[1
]}

Matsuo, Hidemasa ^{[2
]}

Sugiyama, Hiroshi ^{[3
]}

Adachi, Souichi ^{[2
]}

Kamikubo, Yasuhiko

机构：

[1] Kyoto Univ, Grad Sch Med, Dept Hum Hlth Sci, Kyoto, Japan

[2] Kyoto Univ, Dept Human Hlth Sci, Kyoto, Japan

[3] Kyoto Univ, Grad Sch Sci, Dept Chem, Kyoto, Japan

来源：

CANCER SCIENCE | 2021年 / 112卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OE14-7-6

引用

页码：445 / 445

页数：1

共 50 条

[1] EGFR tyrosine kinase inhibitor in advanced non-small cell lung cancer with wild-type EGFR
Wang, Z.
Wu, Y. L.
Yang, J.
Wang, B.
Huang, Y.
Zhou, Q.
Xu, C.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[2] A study of EGFR wild-type non-small cell lung cancer ALK genetic mutation
Wang, Shoufeng
Mao, Naiquan
Zuo, Chuantian
Pan, Hong
Xie, Tong
Huang, Yaoyuan
Pan, Qi
Wu, Junwei
[J]. TRANSLATIONAL CANCER RESEARCH, 2017, 6 (05) : 976 - 980
[3] Cost of care in EGFR mutant versus wild-type non-small cell lung cancer.
Vusqa, Urwat Til
Asawa, Palash
Miller, Katherine
Sethi, Ashish
Rodriguez, Robin Raquel
Friday, Andrew
Finley, Gene Grant
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer
Wang, Duo
Zhou, Jun
Fang, Weimin
Huang, Cuiqing
Chen, Zerong
Fan, Meng
Zhang, Ming-Rong
Xiao, Zeyu
Hu, Kuan
Luo, Liangping
[J]. BIOACTIVE MATERIALS, 2022, 13 : 312 - 323
[5] Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer
Felip, Enriqueta
Metro, Giulio
Tan, Daniel S. W.
Wolf, Juergen
Mark, Michael
Boyer, Michael
Hughes, Brett G. M.
Bearz, Alessandra
Moro-Sibilot, Denis
Le, Xiuning
Puente, Javier
Massuti, Bartomeu
Tiedt, Ralph
Wang, Yingying
Xu, Chao
Mardjuadi, Feby I.
Cobo, Manuel
[J]. LUNG CANCER, 2024, 192
[6] Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
Li, Amin
Cao, Weiya
Liu, Xueke
Zhang, Yinci
Ma, Yongfang
Xu, Ruyue
Zhang, Rongbo
Liu, Xinkuang
Zhou, Shuping
Wang, Ruikai
Liu, Jiachang
Tang, Xiaolong
[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (07) : 1737 - 1749
[7] Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
Amin Li
Weiya Cao
Xueke Liu
Yinci Zhang
Yongfang Ma
Ruyue Xu
Rongbo Zhang
Xinkuang Liu
Shuping Zhou
Ruikai Wang
Jiachang Liu
Xiaolong Tang
[J]. Journal of Cancer Research and Clinical Oncology, 2020, 146 : 1737 - 1749
[8] Sensitization of EGFR Wild-Type Non-Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib
Raimbourg, Judith
Joalland, Marie-Pierre
Cabart, Mathilde
de Plater, Ludmilla
Bouquet, Fanny
Savina, Ariel
Decaudin, Didier
Bennouna, Jaafar
Vallette, Francois M.
Lalier, Lisenn
[J]. MOLECULAR CANCER THERAPEUTICS, 2017, 16 (08) : 1634 - 1644
[9] Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds
Huang, Yu
Chen, Yu
Mei, Qin
Chen, Yuan
Yu, Shiying
Xia, Shu
[J]. ONCOLOGY REPORTS, 2013, 29 (06) : 2486 - 2492
[10] Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFR
Ren, Shengxiang
Su, Chunxia
Wang, Zhaoye
Li, Jiayu
Fan, Lihong
Li, Bing
Li, Xuefei
Zhao, Cao
Wu, Chunyan
Hou, Likun
He, Yayi
Gao, Guanghui
Chen, Xiaoxia
Ren, Jiawei
Li, Aiwu
Xu, Guotong
Zhou, Xiao
Zhou, Caicun
Schmid-Bindert, Gerald
[J]. INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (12) : 2962 - 2971

← 1 2 3 4 5 →